Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke
https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 2217
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Neoplasms
- Stroke
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Cancer
- Cerebrovascular disease
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 2217
Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 1493
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Subjects (LCSH)
- Chronic renal failure--Complications
- Renal anemia
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1493
Venofer® iron sucrose injection
https://libcat.nshealth.ca/en/permalink/chpams35932
Nova Scotia Health Authority. Yarmouth Regional Hospital. Ambulatory Care (ABC).
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1876
- Available Online
- View Pamphlet
If you do not have enough iron in your blood, your red blood cells will not have enough hemoglobin. Hemoglobin carries oxygen throughout your body. When you do not have enough hemoglobin, your body may have trouble getting enough oxygen. This may cause you to feel tired or short of breath. This is called anemia. Iron sucrose (Venofer®) is an injectable (given by a needle in your arm) form of iron that helps your body make hemoglobin. This pamphlet explains how to take Venofer®, possible side ef…
- Available Online
- View Pamphlet
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([2] p.) : digital, PDF file
- Subjects (MeSH)
- Iron - therapeutic use
- Anemia - drug therapy
- Abstract
- If you do not have enough iron in your blood, your red blood cells will not have enough hemoglobin. Hemoglobin carries oxygen throughout your body. When you do not have enough hemoglobin, your body may have trouble getting enough oxygen. This may cause you to feel tired or short of breath. This is called anemia. Iron sucrose (Venofer®) is an injectable (given by a needle in your arm) form of iron that helps your body make hemoglobin. This pamphlet explains how to take Venofer®, possible side effects, and signs of an allergic reaction.
- Responsibility
- Prepared by: Ambulatory Care (ABC), Yarmouth Regional Hospital
- Pamphlet Number
- 1876
